Thus, cyclophilin A can represent either an adjunctive marker for RAS-mutant NIFTPs, especially in the preoperative settings as a cost-effective IHC marker for FNA triage, and can support the employment of future targeted therapies in RAS-mutant metastatic follicular-patterned thyroid neoplasms. The gene discussed is PPIA; the disease is thyroid tumor.